India, June 22 -- Suven Life Sciences Ltd., a clinical-stage biopharmaceutical company focused on Central Nervous System (CNS) disorders, has announced its participation in the BIO International Convention 2026, one of the world's largest biotechnology partnering events, scheduled to be held from June 22–25 in San Diego, USA.
At the event, Suven will showcase its differentiated CNS portfolio, including late-stage clinical candidates targeting significant unmet medical needs such as agitation in dementia of Alzheimer's type, major depressive disorder, narcolepsy, cognitive impairment associated with Parkinson's disease, and other neurological disorders.
The company aims to engage with global pharmaceutical and biotechnology firms to ...